Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer Clinical research trials and ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer. ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer

ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer



ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer

For Condition: Neoplasms
Status: Recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Phase 1/2 Dose-Escalating Study of Biweekly ALIMTA and Gemcitabine in Patients with Advanced Cancer.
Details:
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: If you participate in Phase 1 portion of the study - Have a diagnosis of a solid tumor cancer, including, but not limited to breast, lung, colon, pancreatic, or sarcoma, and can be treated with chemotherapy. - May have received prior chemotherapy for your disease, but must not include ALIMTA and GEMZAR. - Have at least one measurable lesion. - Have an adequate performance status. - Sign an informed consent form. If you participate in Phase 2 portion of the study - Have a diagnosis of non-small cell lung cancer. - Have not received prior chemotherapy for your disease. - Have at least one measurable lesion. - Have an adequate performance status. - Sign an informed consent form. Exclusion Criteria: - Have been treated with an investigational drug within the last 30 days, have previously completed or withdrawn from this study or any other study investigating ALIMTA. - Have received radiation therapy within the last 1-2 weeks. - Have brain metastasis that is uncontrolled. - Have active infection or other serious condition. - Have a second cancer in addition to Advanced Cancer.
Total Enrollment: 

Location and Contact Information:

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Dallas,  Texas, 
United States
Recruiting  

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Minneapolis,  Minnesota, 
United States
Recruiting  


Additional Information:
Study ID Numbers:  7221; 
Study Start Date: 
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071136

Other Neoplasms Studies:
1. A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients

2. Kanglaite Injection Phase I Study

3. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days

4. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses

5. Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)

Related Studies:

Other Neoplasms Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials

ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer
Modify your Search

  Other Neoplasms Clinical Trials
  Other Texas Clinical Trials
  Other Dallas Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103